CPA
CAPR icon

Capital Performance Advisors’s Capricor Therapeutics CAPR Stock Holding History

Capital Performance Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-91
Closed -$1.38K – 573
2024
Q3 		$1.38K Buy
+91
New +$450 ﹤0.01% 1747

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Performance Advisors's CAPR Position: Q4 2024 in Review

Capital Performance Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2024, closing a stake of 91 shares — an estimated $1.38K sold.

Capital Performance Advisors first reported a position in CAPR in Q3 2024 and held it in 1 quarter. The position peaked at $1.38K in Q3 2024. 108 funds tracked by Wall St. Rank hold CAPR as of Q4 2024.

  • Capital Performance Advisors reported no remaining Capricor Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 91 Capricor Therapeutics shares in Q4 2024, an estimated $1.38K.
  • Capital Performance Advisors first reported a position in Capricor Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Capricor Therapeutics position peaked at $1.38K in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.